• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Dementia patients frequently on medications with minimal benefit

byAshley AaroeandJames Jiang
September 10, 2014
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. More than half of patients with advanced dementia in this study were on medications of questionable benefit.

2. Patients with chewing or swallowing problems, mouth pain, feeding tubes, do-not-resuscitate (DNR) orders, or enrolled in hospice had lower likelihood of being prescribed a medication of questionable benefit.

Evidence Rating Level: 3 (Average)

Study Rundown: Patients with advanced dementia suffer from a terminal illness characterized by significant cognitive, social, and functional impairment. Goals of care in terminal illness should focus on maximizing comfort and quality of life. Previous studies, though limited, suggest that many patients with advanced dementia may be on medications that fail to address this primary goal and in fact provide minimal benefit. This study defined medications of questionable benefit as those deemed ‘never appropriate’ for use in advanced dementia by a previous consensus of experts.

This study confirms that more than half of long-term nursing home patients (53%) with advanced dementia are prescribed at least one of the medications on that list. Most notably the list includes cholinesterase inhibitors and memantine hydrochloride, medications that are commonly prescribed early in the disease process but have minimal benefit for patients with advanced dementia. The use of such medications is decreased in patients with advance directives enrolled in the hospice setting, and in those who require feeding tubes or have difficulty swallowing. This large cross-sectional study suggests that streamlining medications in accordance with goals of care for patients with advanced dementia is an important issue. One limitation of the study is that the list of medications deemed questionably beneficial was determined by expert consensus. Moreover, the cross-sectional design in this case may over-represent prevalence since dementia is a long duration disease.

Click to read the study in JAMA Internal Medicine

Click to read an accompanying editorial in JAMA Internal Medicine

RELATED REPORTS

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

Relevant Reading: Withholding, Discontinuing and Withdrawing Medications in Dementia Patients at the End of Life

In-Depth [cross-sectional study]: This study used data from the prescription-dispensing database of a long-term care pharmacy. Patients were selected based on having data available between 2009-2010, being greater than 65 years of age, and with a diagnosis of advanced dementia characterized by scores on Mini-Mental State Examination (MMSE). Exclusion criteria were length of stay at care facility less than 90 days, small facilities, and any patients with missing data. 5406 patients met criteria for study.

53.9% of patients (2911 patients) were prescribed at least one medication of questionable benefit during a 90-day observation period. Patients with oral problems had a lower likelihood of being prescribed a questionably beneficial medication, including those with chewing problems, swallowing problems, or mouth pain (adjusted odds ratio [AOR]: 0.68; 95% CI: 0.59-0.78), a feeding tube (AOR: 0.58; 95% CI: 0.48-0.70), a do-not-resuscitate (DNR) order (AOR: 0.65; 95% CI: 0.57- 0.75), and who were enrolled in hospice (AOR: 0.69; 95% CI: 0.58-0.82). Of patients that were on at least 1 questionably beneficial medication, the mean (SD) 90-day drug expenditure was higher, at $2317 ($1357), of which 35.2% was attributable to medications of questionable benefit.

More from this author: Walk test linked to quality of life in multiple sclerosis, Deep brain stimulation may be safe for older Parkinson patients, Exome sequencing potentially valuable in diagnosing familial cerebellar ataxias, Functional connectivity similar between autosomal dominant and late onset Alzheimer Disease, Diets rich in omega fatty acids may reduce ALS (Lou Gehrig’s) risk

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: dementia
Previous Post

Updated guidelines for management of sickle cell disease released

Next Post

Conclusions can change following reanalysis of randomized clinical trial data

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Chronic Disease

Decline in gait speed paired with domain-specific cognition decline may be a useful screening assessment for dementia

May 31, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia

May 19, 2022
Next Post
No obesity paradox found between BMI, stroke, and death

Conclusions can change following reanalysis of randomized clinical trial data

Dual PDE3/PDE4 inhibitor may be effective treatment for asthma and COPD

Paradoxical response to beta-2 agonists found in African-Americans, linked to morbidity

Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]

Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.